Chagas disease drug discovery: Toward a new era

Journal of Biomolecular Screening

Volumn 20, Issue 1, 2015, Pages 22-35

  Chatelain, Eric ^a  

^a Drugs for Neglected Diseases initiative (DND)   (Switzerland)

Author keywords

compound progression criteria; drug discovery; secondary assays; translation; Trypanosoma cruzi

Indexed keywords

ANTIPARASITIC AGENT; BENZNIDAZOLE; NIFURTIMOX; POSACONAZOLE; RAVUCONAZOLE; ANTITRYPANOSOMAL AGENT;

CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); DECISION MAKING; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; PARASITE LOAD; REVIEW; TREATMENT FAILURE; TRYPANOSOMA CRUZI; PARASITOLOGY; PHYSIOLOGY; PROCEDURES; RESEARCH; TREATMENT OUTCOME; TRENDS;

TRYPANOSOMA CRUZI;

CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; RESEARCH; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84920081179     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114550585     Document Type: Review

References (111)

1. Rassi A., Rassi A., Marcondes de Rezende J.. American Trypanosomiasis (Chagas Disease). Infect. Dis. Clin. North Am. 2012 ; 26: 275-291
2. Chagas C.. Nova tripanozomiase humana: Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz. 1909 ; 1: 159-218
3. Samuels A. M., Clark E. H., Galdos-Cardenas G., et al. Epidemiology of and Impact of Insecticide Spraying on Chagas Disease in Communities in the Bolivian Chaco. PLoS Neg. Trop. Dis. 2013 ; 7: e2358
4. Estimación cuantitativa de la enfermedad de Chagas en las Américas/Quantitative estimation of Chagas Disease in the Americas. Organización Panamericana de la Salud. Montevideo, Uruguay. 2006 ;:
5. Hotez P. J., Bottazzi M. E., Franco-Peredes C., et al. The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination. PLoS Negl. Trop. Dis. 2008 ; 2: e300
6. Bern C., Kjos S., Yabsley M. J., et al. Trypanosoma cruzi and Chagas' Disease in the United States. Clin. Microbiol. Rev. 2011 ; 24: 655-681
7. Gascon J., Bern C., Pinazo M. J.. Chagas Disease in Spain, the United States and Other Non-Endemic Countries. Acta Trop. 2010 ; 115: 22-27
8. Jackson Y., Pinto A., Pettt S.. Chagas Disease in Australia and New Zealand: Risks and Needs for Public Health Interventions. Trop. Med. Int. Health. 2014 ; 19: 212-218
9. Navarro M., Navaza B., Guionnet A., et al. Chagas Disease in Spain: Need for Further Public Health Measures. PLoS Negl. Trop. Dis. 2012 ; 6: e1962
10. World Health Organization. WHO Fact Sheet No 340. http://www.who.int/mediacentre/factsheets/fs340/en/ (accessed May 29, 2014).
11. Lozano R., Naghavi M., Foreman K., et al. Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet. 2012 ; 380: 2095-2128
12. Martins-Melo F. R., Alencar C. H., Ramos A. N., et al. Epidemiology of Mortality Related to Chagas' Disease in Brazil, 1999-2007. PLoS Negl. Trop. Dis. 2012 ; 6: e1508
13. Moolani Y., Bukhman G., Hotez P. J.. Neglected Tropical Diseases as Hidden Causes of Cardiovascular Disease. PLoS Negl. Trop. Dis. 2012 ; 6: e1499
14. Hotez P. J.. Neglected Diseases and Poverty in "The Other America": The Greatest Health Disparity in the United States?. PLoS Negl. Trop. Dis. 2007 ; 1: e149
15. Hotez P. J., Dumonteil E., Heffeman M. J., et al. Innovation for the "Bottom 100 Million": Eliminating Neglected Tropical Diseases in the Americas. Adv. Exp. Med. Biol. 2013 ; 764: 1-12
16. Mathers C. D., Ezzati M., Lopez A. D.. Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework. PLoS Negl. Trop. Dis. 2007 ; 1: e114
17. Lee B. Y., Bacon K. M., Bottazzi M. E., et al. Global Economic Burden of Chagas Disease: A Computational Simulation Model. Lancet Infect. Dis. 2013 ; 13: 342-348
18. Sanchez L. V., Ramirez J. D.. Congenital and Oral Transmission of American Trypanosomiasis: An Overview of Physiopathogenic Aspects. Parasitology. 2013 ; 140: 147-159
19. Dias J. C., Amato Neto V.. Prevention Concerning the Different Alternative Routes for Transmission of Trypanosoma cruzi in Brazil. Rev. Soc. Bras. Med. Trop. 2011 ; 44: 68-72
20. Alarcón de Noya B., Díaz-Bello Z., Colmenares C., et al. Large Urban Outbreak of Orally Acquired Acute Chagas Disease at a School in Caracas, Venezuela. J. Infect. Dis. 2010 ; 201: 1308-1315
21. Pereira K. S., Schmidt F. L, Guaraldo A. M., et al. Chagas' Disease as a Foodborne Illness. J. Food. Prot. 2009 ; 72: 441-446
22. Tarleton R. L. American Trypanosomiasis. Tyler K. M. Miles M. A., ed. Springer: New York ; 2003: 107-116.
23. Dubner S., Schapachnik E., Riera A. R, et al. Chagas Disease: State-of-the-Art of Diagnosis and Management. Cardiol. J. 2008 ; 15: 493-504
24. Rassi A., Rassi A., Marin-Neto J. A.. Chagas Disease. Lancet. 2010 ; 375: 1388-1402
25. Berrizbeitia M., Ndao M., Bubis J., et al. Field Evaluation of Four Novel Enzyme Immunoassays for Chagas Disease in Venezuela Blood Banks: Comparison of Assays Using Fixed-Epimastigotes, Fixed-Trypomastigotes or Trypomastigote Excreted-Secreted Antigens Two Trypanosoma cruzi Strains. Transfus. Med. 2006 ; 16: 419-431
26. Da Silveira J. F., Umezawa E. S., Luquetti A. O.. Chagas Disease: Recombinant Trypanosoma cruzi Antigens for Serological Diagnosis. Trends Parasitol. 2001 ; 17: 286-291
27. Brasil P. E., De C. L., Hasslocher-Moreno A. M., et al. ELISA versus PCR for Diagnosis of Chronic Chagas Disease: Systematic Review and Meta-Analysis. BMC Infect. Dis. 2010 ; 10: 337
28. Camargo M. E., Segura E. L., Kagan I. G., et al. Three Years of Collaboration on the Standardization of Chagas' Disease Serodiagnosis in the Americas: An Appraisal. Bull. Pan. Am. Health Organ. 1986 ; 20: 233-244
29. Coura J. R., Borges-Pereira J.. Chronic Phase of Chagas Disease: Why Should It Be Treated? A Comprehensive Review. Mem. Inst. Oswaldo Cruz. 2011 ; 106: 641-645
30. Ayub-Ferreira S. M., Mangini S., Issa V. S., et al. Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective Trial. PLoS Negl. Trop. Dis. 2013 ; 7: e2176
31. Tyler K. M., Engman D. M.. The Life Cycle of Trypanosoma cruzi Revisited. Int. J. Parasitol. 2001 ; 31: 472-481
32. Goldenberg S., Avila A. R.. Aspects of Trypanosoma cruzi Stage Differentiation. Adv. Parasitol. 2011 ; 75: 285-305
33. Panunzi L. G., Agüero F.. A Genome-Wide Analysis of Genetic Diversity in Trypanosoma cruzi Intergenic Regions. PLoS Negl. Trop. Dis. 2014 ; 8: e2839
34. Zingales B., Andrade S. G., Briones M. R., et al. A New Consensus for Trypanosoma cruzi Intraspecific Nomenclature: Second Revision Meeting Recommends TcI to TcVI. Mem. Inst. Oswaldo Cruz. 2009 ; 104: 1051-1054
35. Zingales B., Miles M. A., Campbell D. A., et al. The Revised Trypanosoma cruzi Subspecific Nomenclature: Rationale, Epidemiological Relevance and Research Applications. Infect. Genet. Evol. 2012 ; 12: 240-253
36. Guhl F., Ramirez J. D.. Trypanosoma cruzi I Diversity: Towards the Need of Genetic Subdivision?. Acta Trop. 2011 ; 119: 1-4
37. Perez C. J., Lymbery A. J., Thompson R. C. A.. Chagas Disease: The Challenge of Polyparasitism?. Trends Parasitol. 2014 ; 30: 176-182
38. Castro J. A., de Mecca M. M., Bartel L. C.. Toxic Side Effects of Drugs Used to Treat Chagas' Disease (American Trypansosomiasis). Hum. Exp. Toxicol. 2006 ; 25: 471-479
39. Viotti R., Vigliano C., Alvarez M. G., et al. Side Effects of Benznidazole as Treatment in Chronic Chagas Disease: Fears and Realities. Expert Rev. Anti Infect. Ther. 2009 ; 7: 157-163
40. Guedes P. M., Silva G. K., Gutierrez F. R., et al. Current Status of Chagas Disease. Expert Rev. Anti Infect. Ther. 2011 ; 9: 609-620
41. Pinto Dias J. C., Coura J. R., Yasuda M. A. S.. The Present Situation, Challenges, and Perspectives Regarding the Production and Utilization of Effective Drugs against Human Chagas Disease. Rev. Soc. Bras. Med. Trop. 2014 ; 47: 123-125
42. Clayton J.. Chagas Disease: Pushing through the Pipeline. Nature. 2010 ; 465: S12 - S15
43. Soeiro M. N. C., Dantas A. P., Daliry A., et al. Experimental Chemotherapy for Chagas Disease: 15 Years of Research Contributions from In Vivo and In Vitro Studies. Mem. Inst. Oswaldo Cruz. 2009 ; 104: 301-310
44. Soeiro M. N. C., de Castro S. L.. Screening of Potential Anti-Trypanosoma cruzi Candidates: In vitro and In Vivo Studies. Open Med. Chem. J. 2011 ; 5: 21-30
45. Silva J. J., Guedes P. M., Zottis A., et al. Novel Ruthenium Complexes as Potential Drugs for Chagas' Disease: Enzyme Inhibition and In Vitro/In Vivo Trypanocidal Activity. Br. J. Pharmacol. 2010 ; 160: 260-269
46. Demoro B., Rossi M., Caruso F., et al. Potential Mechanism of the Anti-Trypanosomal Activity of Organoruthenium Complexes with Bioactive Thiosemicarbazones. Biol. Trace Elem. Res. 2013 ; 153: 371-381
47. Buckner F. S., Navabi N.. Advances in Chagas Disease Drug Development: 2009-2010. Curr. Opin. Infect. Dis. 2010 ; 23: 609-616
48. Moreira D. R., Leite A. C., dos Santos R. R., et al. Approaches for the Development of New Anti-Trypanosoma cruzi Agents. Curr. Drug Targets. 2009 ; 10: 212-231
49. Duschak V. G.. A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease. Recent Pat. Antiinfect. Drug Discov. 2011 ; 6: 216-259
50. Chatelain E., Ioset J.-R.. Drug Discovery and Development for Neglected Diseases: The DNDi Model. Drug Des. Dev. Ther. 2011 ; 5: 175-181
51. Bustamante J. M., Park H. J., Tarleton R. L., et al. Report of the 2nd Chagas Drug Discovery Consortium Meeting, Held on 3 November 2010; Atlanta GA, USA. Expert Opin. Drug Discov. 2011 ; 6: 965-973
52. CORDIS; Seventh Framework Programme (FP7). http://cordis.europa.eu/fp7/projects-en.html (accessed and searched May 30, 2014).
53. £10 Million Boost for Neglected Tropical Disease Research, Dundee University, GSK and Wellcome Trust Enter Five-Year Collaboration for Neglected Diseases. Dundee University homepage, http://www.dundee.ac.uk/research/main/news/20110512113509/821.html (accessed May 30, 2014).
54. Commitment to Patients in Both Developed and Developing World. Novartis Institutes for Biomedical research homepage, http://www.nibr.com/newsroom/stories/2012Jan20-ChagasPeople.shtml (accessed May 30, 2014).
55. Eisai Enters Global Agreement with Broad Institute to Develop New Drugs for Neglected Tropical Diseases and Tuberculosis; Drug Discovery Project for Chagas Disease Awarded GHIT Fund Grant. Eisai homepage, http://www.eisai.com/news/news201364.html (accessed May 30, 2014).
56. Tres Cantos Open Lab Foundation homepage, http://openlabfoundation.org/ (accessed May 30, 2014).
57. Payne D. J., Gwynn M. N., Holmes D. J., et al. Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery. Nature Rev. Drug Discov. 2007 ; 6: 29-40
58. Torreele E., Bourdin Trunz B., Tweats D., et al. Fexinidazole: A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness. PLoS Negl. Trop. Dis. 2010 ; 4: e923
59. Bahia M. T., de Andrade I. M., Martins T. A., et al. Fexinidazole: A Potential New Drug Candidate for Chagas Disease. PLoS Negl. Trop. Dis. 2012 ; 6: e1870
60. Bahia M. T., Nascimento A. F., Mazzeti A. L., et al. Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease. Antimicrob. Agents Chemother. 2014 ; 58: 4362-4370
61. Jacobs R. T., Plattner J. J., Keenan M.. Boron-Based Drugs as Antiprotozoals. Curr. Opin. Infect. Dis. 2011 ; 24: 586-592
62. Bustamante J. M., Craft J. M., Crowe B. D., et al. New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice. J. Infect. Dis. 2014 ; 209: 150-162
63. Keenan M., Abbott M. J., Alexander P. W., et al. Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease. J. Med. Chem. 2012 ; 55: 4189-4204
64. CarmodyL. C.GermainA.BarkerD.. Identification of Small-Molecule Inhibitors of Trypanosoma cruzi Infection. 2010Mar25 [updated 2011Feb10]. In: Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information (US): Bethesda, MD, 2010. http://www.ncbi.nlm.nih.gov/books/NBK55071/.
65. Keenan M., Alexander P. W., Chaplin J. H., et al. Selection and Optimization of Hits from a High-Throughput Phenotypic Screen against Trypanosoma cruzi. Future Med. Chem. 2013 ; 5: 1733-1752
66. Romanha A. J., de Castro S. L., Soeiro M. N. C., et al. In Vitro and In Vivo Experimental Models for Drug Screening and Development for Chagas Disease. Mem. Inst. Oswaldo Cruz. 2010 ; 105: 233-238
67. Villar J. C., Perez J. G., Cortes O. L., et al. Trypanocidal Drugs for Chronic Asymptomatic Trypanosoma cruzi Infection. Cochrane Database Syst. Rev. 2014 ; 5: CD003463
68. Marin-Neto J. A., Rassi A., Morillo C. A., et al. Rationale and Design of a Randomized Placebo-Controlled Trial Assessing the Effects of Etiologic Treatment in Chagas' Cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). 1. Am. Heart J. 2008 ; 156: 37-43
69. Marin-Neto J. A., Rassi A., Avezum A., et al. The BENEFIT Trial: Testing the Hypothesis That Trypanocidal Drugs Is Beneficial for Patients with Chronic Chagas Heart Disease. Mem. Inst. Oswaldo Cruz. 2009 ; 104: 319-324
70. Molina I., Gómez I, Prat J., Salvador F., et al. Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease. N. Engl. J. Med. 2014 ; 370: 1899-1908
71. Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease. https://clinicaltrials.gov/ct2/show/NCT01489228?term=e1224+chagas&rank=1. ClinicalTrials.gov Identifier NCT01489228
72. A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS). https://clinicaltrials.gov/ct2/show/NCT01377480?term=chagas+merck&rank=1. ClinicalTrials.gov identifier NCT01377480.
73. Sabino E. C., Lee T. H., Montalvo L., et al. Antibody Levels Correlate with Detection of Trypanosoma cruzi DNA by Sensitive Polymerase Chain Reaction Assays in Seropositive Blood Donors and Possible Resolution of Infection over Time. Transfusion. 2013 ; 53: 1257-1265
74. Zhang L., Tarleton R. L.. Parasite Persistence Correlates with Disease Severity and Localization in Chronic Chagas' Disease. J. Infect. Dis. 1999 ; 180: 480-486
75. Andrade L. O., Andrews N. W.. The Trypanosoma cruzi-Host Cell Interplay: Location, Invasion, Retention. Nat. Rev. Microbiol. 2005 ; 3: 819-823
76. Norman F. F., Pérez-Ayala A., Pérez-Molina J. A., et al. Lack of Correlation between Blood-Based Detection of Trypanosoma cruzi DNA and Cardiac Involvement in a Non-Endemic Area. Ann. Trop. Med. Parasitol. 2011 ; 105: 425-430
77. Schijman A. G., Bisio M., Orellana A. M., et al. International Study to Evaluate PCR Methods for Detection of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. PLoS Negl. Trop. Dis. 2011 ; 5: e931
78. Pinazo M.-J., Thomas M. C., Bua J., et al. Biological Markers for Evaluating Therapeutic Efficacy in Chagas Disease, a Systematic Review. Expert Rev. Anti Infect. Ther. 2014 ; 12: 479-496
79. Ullmann A. J., Cornely O. A., Burchardt A., et al. Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. Antimicrob. Agents Chemother. 2006 ; 50: 658-666
80. Nomeir A. A., Kumari P., Hilbert M. J., et al. Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs and Cynomolgus Monkeys. Antimicrob. Agents Chemother. 2000 ; 44: 727-731
81. Molina J., Martins-Filho O., Brener Z., et al. Activities of the Triazole SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob. Agents Chemother. 2000 ; 44: 150-155
82. Pinazo M.-J., Espinosa G., Gállego M., et al. Case Report: Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus Erythematosus. Am. J. Trop. Med. Hyg. 2010 ; 82: 583-587
83. Burrows J. N., van Huijsduijnen R. H., Möhrle J. J., et al. Designing the Next Generation of Medicines for Malaria Control and Eradication. Malaria J. 2013 ; 12: 187
84. Diniz L., de F., Caldas I. S., Guedes P. M., et al. Effects of Ravuconazole Treatment Onparasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 2010 ; 54: 2979-2986
85. Urbina J. A., Payares G., Contreras L. M., et al. Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: In Vitro and In Vivo Studies. Antimicrob. Agents Chemother. 1998 ; 42: 1771-1777
86. Olivieri B. P., Molina J. T., de Castro S. L., et al. A Comparative Study of Posaconazole and Benznidazole in the Prevention of Heart Damage and Promotion of Trypanocidal Immune Response in a Murine Model of Chagas Disease. Int. J. Antimicrob. Agents. 2010 ; 36: 79-83
87. Lepesheva G. I., Villalta F., Waterman M. R.. Targeting Trypanosoma cruzi Sterol 14α-Demethylase (CYP51). Adv. Parasitol. 2011 ; 75: 65-87
88. Buckner F. S., Bahia M. T., Suryadevara P. K., et al. Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib. Antimicrob. Agents Chemother. 2012 ; 56: 4914-4921
89. Hargrove T. Y., Wawrzak Z., Alexander P. W., et al. Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-Based Drug Candidates for Chagas Disease: Structural Basis for Pathogen Selectivity. J. Biol. Chem. 2013 ; 288: 31602-31615
90. Soeiro Mde. N., de Souza E. M., da Silva C. F., et al. In Vitro and In Vivo Studies of the Anti-Parasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 2013 ; 57: 4151-4163
91. Festing M. F. W.. The Need for Better Experimental Design. TIPS. 2003 ; 24: 341-345
92. Buckner F. S.. Experimental Chemotherapy and Approaches to Drug Discovery for Trypanosoma cruzi Infection. Adv. Parasitol. 2011 ; 75: 89-119
93. Bustamante J. M., Tarleton R. L.. Methodological Advances in Drug Discovery. Expert Opin. Drug Disc. 2011 ; 6: 653-661
94. Buckner F. S., Verlinde C. L., La Flamme A. C., et al. Efficient Technique for Screening Drugs for Activity against Trypanosoma cruzi Using Parasites Expressing Beta-Galactosidase. Antimicrob. Agents Chemother. 1996 ; 40: 2592-2597
95. Canavaci A. M. C., Bustamante J. M., Padilla A. M., et al. In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds. PLoS Negl. Trop. Dis. 2010 ; 4: e740
96. Nohara L. L., Lema C., Bader J. O., et al. High-Content Imaging for Automated Determination of Host-Cell Interaction Rate by the Intracellular Parasite Trypanosoma cruzi. Parasitol Int. 2010 ; 59: 565-570
97. Engel J. C., Ang K. K., Chen S., et al. Image-Based High-Throughput Drug Screening Targeting the Intracllular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease. Antimicrob. Agents Chemother. 2010 ; 54: 3326-3334
98. Moon S., Siqueira-Neto J. L., Moraes C. B., et al. An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi. PLoS One. 2014 ; 9: e8718
99. Moraes C. B., Giardini M. A., Kim H., et al. Nitroheterocyclic Compounds Are More Efficacious Than CYP51 Inhibitors against Trypanosoma cruzi: Implications for Chagas Disease Drug Discovery and Development. Sci. Rep. 2014 ; 4: 4703
100. Hernandez-Osorio L. A., Marquez-Dueñas C., Florencio-Martinez L. E., et al. Improved Methods for In Vitro Secondary Amastigogenesis of Trypanosoma cruzi: Morphometrical and Molecular Analysis of Intermediate Developmental Forms. J. Biomed. Biotechnol. 2010 ; 2010: 283842
101. Sanz L. M., Crespo B., De-Cózar C., et al. P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action. PLoS One. 2012 ; 7: e30949
102. Nare B., Wring S., Bacchi C., et al. Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis. Antimicrob. Agents Chemother. 2010 ; 54: 4379-4388
103. Bettiol E., Samanovic M., Murkin A. S., et al. Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library Screening. PLoS Negl. Trop. Dis. 2009 ; 3: e384
104. Franzén O., Ochaya S., Sherwood E., et al. Shotgun Sequencing Analysis of Trypanosoma cruzi I Sylvio X10/1 and Comparison with T. cruzi VI CL Brener. PLoS Negl. Trop. Dis. 2011 ; 5: e984
105. Menna-Barreto R. F., Perales J.. The Expected Outcome of the Trypanosoma cruzi Proteomic Map: Review of Its Potential Biological Applications for Drug Target Discovery. Subcell. Biochem. 2014 ; 74: 305-322
106. Trochine A., Creek D. J., Faral-Tello P., et al. Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics. PLoS Negl. Trop. Dis. 2014 ; 8: e2844
107. Smirlis D., Soares M. B.. Selection of Molecular Targets for Drug Development against Trypanosomatids. Subcell. Biochem. 2014 ; 74: 43-76
108. Cosentino R. O., Agüero F.. Genetic Profiling of the Isoprenoid and Sterol Biosynthesis Pathway Genes of Trypanosoma cruzi. PLoS One. 2014 ; 9: 96762
109. Andriani G., Chessler A. D., Courtemanche G., et al. Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening. PLoS Negl. Trop. Dis. 2011 ; 5: e1298
110. Lewis M. D., Fortes Francisco A., Taylor M. C., et al. Bioluminescence Imaging of Chronic Trypanosoma cruzi Infections Reveals Tissue-Specific Parasite Dynamics and Heart Disease in the Absence of Locally Persistent Infection. Cell Microbiol. 2014 ;:
111. Santamaria C., Chatelain E., Jackson Y., et al. Serum Biomarkers Predictive of Cure in Chagas Disease Patients after Nifurtimox Treatment. BMC Infect. Dis. 2014 ; 14: 302